Advertisement

Epigenetic Changes and Epigenetic Targets in Head and Neck Cancer

  • Suraj Peri
  • Andrew J. Andrews
  • Aarti Bhatia
  • Ranee Mehra
Chapter
Part of the Current Cancer Research book series (CUCR)

Abstract

Epigenetic changes are both inheritable and reversible, affecting the spatial conformation of DNA and its transcriptional activity. The most common classes of epigenetic regulation include modification of DNA (typically by methylation), or modification of the histones that form nucleosomes (typically by methylation, acetylation, or phosphorylation). Epigenetic changes can influence gene expression patterns without making permanent changes in DNA. In this article, we discuss characteristic changes in the epigenetic modification of tumor DNA that occurs in squamous cell carcinomas of the head and neck (SCCHN), which controls the selective induction and repression of genes relevant to the disease pathology. We also describe key proteins that mediate epigenetic control of gene expression, and emerging therapeutic approaches to target epigenetic control systems.

Keywords

Epigenetics DNA methylation Histone methylation Histone acetylation TCGA NSD1 NSD2 H3K36 H3K27 Tobacco Smoking 

References

  1. 1.
    Agrawal N, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science. 2011;333:1154–7.  https://doi.org/10.1126/science.1206923.CrossRefPubMedCentralPubMedGoogle Scholar
  2. 2.
    Cancer Genome Atlas, N. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015;517:576–82.  https://doi.org/10.1038/nature14129.CrossRefGoogle Scholar
  3. 3.
    Stransky N, et al. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011;333:1157–60.  https://doi.org/10.1126/science.1208130.CrossRefPubMedCentralPubMedGoogle Scholar
  4. 4.
    Beck TN, Golemis EA. Genomic insights into head and neck cancer. Cancers Head Neck. 2016;1.  https://doi.org/10.1186/s41199-016-0003-z.
  5. 5.
    Cancer Genome Atlas Research, N. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013;499:43–9.  https://doi.org/10.1038/nature12222.CrossRefGoogle Scholar
  6. 6.
    Seiwert TY, et al. Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. Clin Cancer Res. 2015;21:632–41.  https://doi.org/10.1158/1078-0432.CCR-13-3310.CrossRefGoogle Scholar
  7. 7.
    Ha PK, Califano JA. Promoter methylation and inactivation of tumour-suppressor genes in oral squamous-cell carcinoma. Lancet Oncol. 2006;7:77–82.  https://doi.org/10.1016/S1470-2045(05)70540-4.CrossRefGoogle Scholar
  8. 8.
    Smith IM, Mydlarz WK, Mithani SK, Califano JA. DNA global hypomethylation in squamous cell head and neck cancer associated with smoking, alcohol consumption and stage. Int J Cancer. 2007;121:1724–8.  https://doi.org/10.1002/ijc.22889.CrossRefGoogle Scholar
  9. 9.
    Tokumaru Y, et al. Inverse correlation between cyclin A1 hypermethylation and p53 mutation in head and neck cancer identified by reversal of epigenetic silencing. Cancer Res. 2004;64:5982–7.  https://doi.org/10.1158/0008-5472.CAN-04-0993.CrossRefGoogle Scholar
  10. 10.
    Baylin SB, Jones PA. A decade of exploring the cancer epigenome – biological and translational implications. Nat Rev Cancer. 2011;11:726–34.  https://doi.org/10.1038/nrc3130.CrossRefPubMedCentralPubMedGoogle Scholar
  11. 11.
    Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell. 2012;150:12–27.  https://doi.org/10.1016/j.cell.2012.06.013.CrossRefGoogle Scholar
  12. 12.
    Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer. 2004;4:143–53.  https://doi.org/10.1038/nrc1279.CrossRefGoogle Scholar
  13. 13.
    Robertson KD. DNA methylation and human disease. Nat Rev Genet. 2005;6:597–610.  https://doi.org/10.1038/nrg1655.CrossRefGoogle Scholar
  14. 14.
    Cedar H, Bergman Y. Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet. 2009;10:295–304.  https://doi.org/10.1038/nrg2540.CrossRefGoogle Scholar
  15. 15.
    Schumacher A, et al. Microarray-based DNA methylation profiling: technology and applications. Nucleic Acids Res. 2006;34:528–42.  https://doi.org/10.1093/nar/gkj461.CrossRefPubMedCentralPubMedGoogle Scholar
  16. 16.
    Yong WS, Hsu FM, Chen PY. Profiling genome-wide DNA methylation. Epigenetics Chromatin. 2016;9:26.  https://doi.org/10.1186/s13072-016-0075-3.CrossRefPubMedCentralPubMedGoogle Scholar
  17. 17.
    Bock C. Analysing and interpreting DNA methylation data. Nat Rev Genet. 2012;13:705–19.  https://doi.org/10.1038/nrg3273.CrossRefGoogle Scholar
  18. 18.
    Chelaru F, Smith L, Goldstein N, Bravo HC. Epiviz: interactive visual analytics for functional genomics data. Nat Methods. 2014;11:938–40.  https://doi.org/10.1038/nmeth.3038.CrossRefPubMedCentralPubMedGoogle Scholar
  19. 19.
    Kent WJ, Zweig AS, Barber G, Hinrichs AS, Karolchik D. BigWig and BigBed: enabling browsing of large distributed datasets. Bioinformatics. 2010;26:2204–7.  https://doi.org/10.1093/bioinformatics/btq351.CrossRefPubMedCentralPubMedGoogle Scholar
  20. 20.
    Raney BJ, et al. Track data hubs enable visualization of user-defined genome-wide annotations on the UCSC genome browser. Bioinformatics. 2014;30:1003–5.  https://doi.org/10.1093/bioinformatics/btt637.CrossRefGoogle Scholar
  21. 21.
    Thorvaldsdottir H, Robinson JT, Mesirov JP. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform. 2013;14:178–92.  https://doi.org/10.1093/bib/bbs017.CrossRefGoogle Scholar
  22. 22.
    Bellacosa A, Drohat AC. Role of base excision repair in maintaining the genetic and epigenetic integrity of CpG sites. DNA Repair. 2015;32:33–42.  https://doi.org/10.1016/j.dnarep.2015.04.011.
  23. 23.
    Chen T, Li E. Structure and function of eukaryotic DNA methyltransferases. Curr Top Dev Biol. 2004;60:55–89.  https://doi.org/10.1016/S0070-2153(04)60003-2.CrossRefGoogle Scholar
  24. 24.
    Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell. 1999;99:247–57.CrossRefGoogle Scholar
  25. 25.
    Chen ZX, Mann JR, Hsieh CL, Riggs AD, Chedin F. Physical and functional interactions between the human DNMT3L protein and members of the de novo methyltransferase family. J Cell Biochem. 2005;95:902–17.  https://doi.org/10.1002/jcb.20447.CrossRefGoogle Scholar
  26. 26.
    Suetake I, Shinozaki F, Miyagawa J, Takeshima H, Tajima S. DNMT3L stimulates the DNA methylation activity of Dnmt3a and Dnmt3b through a direct interaction. J Biol Chem. 2004;279:27816–23.  https://doi.org/10.1074/jbc.M400181200.CrossRefGoogle Scholar
  27. 27.
    Kohli RM, Zhang Y. TET enzymes, TDG and the dynamics of DNA demethylation. Nature. 2013;502:472–9.  https://doi.org/10.1038/nature12750.CrossRefPubMedCentralPubMedGoogle Scholar
  28. 28.
    Pastor WA, Aravind L, Rao A. TETonic shift: biological roles of TET proteins in DNA demethylation and transcription. Nat Rev Mol Cell Biol. 2013;14:341–56.  https://doi.org/10.1038/nrm3589.CrossRefPubMedCentralPubMedGoogle Scholar
  29. 29.
    Kuroda A, et al. Insulin gene expression is regulated by DNA methylation. PLoS One. 2009;4:e6953.  https://doi.org/10.1371/journal.pone.0006953.CrossRefPubMedCentralPubMedGoogle Scholar
  30. 30.
    Nan X, et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature. 1998;393:386–9.  https://doi.org/10.1038/30764.CrossRefPubMedGoogle Scholar
  31. 31.
    Lister R, et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature. 2009;462:315–22.  https://doi.org/10.1038/nature08514.CrossRefPubMedCentralPubMedGoogle Scholar
  32. 32.
    Maunakea AK, et al. Conserved role of intragenic DNA methylation in regulating alternative promoters. Nature. 2010;466:253–7.  https://doi.org/10.1038/nature09165.CrossRefPubMedCentralPubMedGoogle Scholar
  33. 33.
    Yang X, et al. Gene body methylation can alter gene expression and is a therapeutic target in cancer. Cancer Cell. 2014;26:577–90.  https://doi.org/10.1016/j.ccr.2014.07.028.CrossRefPubMedCentralPubMedGoogle Scholar
  34. 34.
    Hellman A, Chess A. Gene body-specific methylation on the active X chromosome. Science. 2007;315:1141–3.  https://doi.org/10.1126/science.1136352.CrossRefPubMedGoogle Scholar
  35. 35.
    Shukla S, et al. CTCF-promoted RNA polymerase II pausing links DNA methylation to splicing. Nature. 2011;479:74–9.  https://doi.org/10.1038/nature10442.CrossRefPubMedGoogle Scholar
  36. 36.
    Jones P, The A. DNA methylation paradox. Trends Genet. 1999;15:34–7.CrossRefPubMedGoogle Scholar
  37. 37.
    Portela A, Esteller M. Epigenetic modifications and human disease. Nat Biotechnol. 2010;28:1057–68.  https://doi.org/10.1038/nbt.1685.CrossRefPubMedGoogle Scholar
  38. 38.
    Zilberman D, Gehring M, Tran RK, Ballinger T, Henikoff S. Genome-wide analysis of Arabidopsis thaliana DNA methylation uncovers an interdependence between methylation and transcription. Nat Genet. 2007;39:61–9.  https://doi.org/10.1038/ng1929.CrossRefPubMedGoogle Scholar
  39. 39.
    Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet. 2012;13:484–92.  https://doi.org/10.1038/nrg3230.CrossRefPubMedGoogle Scholar
  40. 40.
    Neri F, et al. Intragenic DNA methylation prevents spurious transcription initiation. Nature. 2017;543:72–7.  https://doi.org/10.1038/nature21373.CrossRefPubMedGoogle Scholar
  41. 41.
    Wagner EJ, Carpenter PB. Understanding the language of Lys36 methylation at histone H3. Nat Rev Mol Cell Biol. 2012;13:115–26.  https://doi.org/10.1038/nrm3274.CrossRefPubMedCentralPubMedGoogle Scholar
  42. 42.
    Doi A, et al. Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat Genet. 2009;41:1350–3.  https://doi.org/10.1038/ng.471.CrossRefPubMedCentralPubMedGoogle Scholar
  43. 43.
    Irizarry RA, et al. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet. 2009;41:178–86.  https://doi.org/10.1038/ng.298.CrossRefPubMedCentralPubMedGoogle Scholar
  44. 44.
    Ji H, et al. Comprehensive methylome map of lineage commitment from haematopoietic progenitors. Nature. 2010;467:338–42.  https://doi.org/10.1038/nature09367.CrossRefPubMedCentralPubMedGoogle Scholar
  45. 45.
    Straussman R, et al. Developmental programming of CpG island methylation profiles in the human genome. Nat Struct Mol Biol. 2009;16:564–71.  https://doi.org/10.1038/nsmb.1594.CrossRefPubMedGoogle Scholar
  46. 46.
    Kacem S, Feil R. Chromatin mechanisms in genomic imprinting. Mamm Genome. 2009;20:544–56.  https://doi.org/10.1007/s00335-009-9223-4.CrossRefPubMedGoogle Scholar
  47. 47.
    Hashibe M, et al. Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the international head and neck Cancer epidemiology consortium. J Natl Cancer Inst. 2007;99:777–89.  https://doi.org/10.1093/jnci/djk179.CrossRefPubMedGoogle Scholar
  48. 48.
    Maasland DH, van den Brandt PA, Kremer B, Goldbohm RA, Schouten LJ. Alcohol consumption, cigarette smoking and the risk of subtypes of head-neck cancer: results from the Netherlands Cohort Study. BMC Cancer. 2014;14:187.  https://doi.org/10.1186/1471-2407-14-187.CrossRefPubMedCentralPubMedGoogle Scholar
  49. 49.
    Shaw R, Beasley N. Aetiology and risk factors for head and neck cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol. 2016;130:S9–S12.  https://doi.org/10.1017/S0022215116000360.CrossRefPubMedCentralPubMedGoogle Scholar
  50. 50.
    Busch R, et al. Differential DNA methylation marks and gene comethylation of COPD in African-Americans with COPD exacerbations. Respir Res. 2016;17:143.  https://doi.org/10.1186/s12931-016-0459-8.CrossRefPubMedCentralPubMedGoogle Scholar
  51. 51.
    Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst. 1999;91:1194–210.CrossRefPubMedGoogle Scholar
  52. 52.
    Ligthart S, et al. DNA methylation signatures of chronic low-grade inflammation are associated with complex diseases. Genome Biol. 2016;17:255.  https://doi.org/10.1186/s13059-016-1119-5.CrossRefPubMedCentralPubMedGoogle Scholar
  53. 53.
    Sundar IK, et al. DNA methylation profiling in peripheral lung tissues of smokers and patients with COPD. Clin Epigenetics. 2017;9:38.  https://doi.org/10.1186/s13148-017-0335-5.CrossRefPubMedCentralPubMedGoogle Scholar
  54. 54.
    Joehanes R, et al. Epigenetic signatures of cigarette smoking. Circ Cardiovasc Genet. 2016;9:436–47.  https://doi.org/10.1161/CIRCGENETICS.116.001506.CrossRefPubMedCentralPubMedGoogle Scholar
  55. 55.
    Feil R, Fraga MF. Epigenetics and the environment: emerging patterns and implications. Nat Rev Genet. 2012;13:97–109.  https://doi.org/10.1038/nrg3142.CrossRefPubMedGoogle Scholar
  56. 56.
    Ziller MJ, et al. Charting a dynamic DNA methylation landscape of the human genome. Nature. 2013;500:477–81.  https://doi.org/10.1038/nature12433.CrossRefPubMedCentralPubMedGoogle Scholar
  57. 57.
    Wan ES, et al. Smoking-associated site-specific differential methylation in buccal mucosa in the COPDGene study. Am J Respir Cell Mol Biol. 2015;53:246–54.  https://doi.org/10.1165/rcmb.2014-0103OC.CrossRefPubMedCentralPubMedGoogle Scholar
  58. 58.
    Sankaranarayanan R, Masuyer E, Swaminathan R, Ferlay J, Whelan S. Head and neck cancer: a global perspective on epidemiology and prognosis. Anticancer Res. 1998;18:4779–86.PubMedGoogle Scholar
  59. 59.
    Wang TH, Hsia SM, Shih YH, Shieh TM. Association of smoking, alcohol use, and betel quid chewing with epigenetic aberrations in cancers. Int J Mol Sci. 2017;18.  https://doi.org/10.3390/ijms18061210.
  60. 60.
    Scott RS. Epstein-Barr virus: a master epigenetic manipulator. Curr Opin Virol. 2017;26:74–80.  https://doi.org/10.1016/j.coviro.2017.07.017.CrossRefGoogle Scholar
  61. 61.
    Chen CJ, et al. Multiple risk factors of nasopharyngeal carcinoma: Epstein-Barr virus, malarial infection, cigarette smoking and familial tendency. Anticancer Res. 1990;10:547–53.Google Scholar
  62. 62.
    Goelz SE, Vogelstein B, Hamilton SR, Feinberg AP. Hypomethylation of DNA from benign and malignant human colon neoplasms. Science. 1985;228:187–90.CrossRefGoogle Scholar
  63. 63.
    Belinsky SA, et al. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA. 1998;95:11891–6.CrossRefGoogle Scholar
  64. 64.
    Arantes LM, de Carvalho AC, Melendez ME, Carvalho AL, Goloni-Bertollo EM. Methylation as a biomarker for head and neck cancer. Oral Oncol. 2014;50:587–92.  https://doi.org/10.1016/j.oraloncology.2014.02.015.CrossRefGoogle Scholar
  65. 65.
    Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet. 1999;21:163–7.  https://doi.org/10.1038/5947.CrossRefPubMedGoogle Scholar
  66. 66.
    Sadikovic B, Al-Romaih K, Squire JA, Zielenska M. Cause and consequences of genetic and epigenetic alterations in human cancer. Curr Genomics. 2008;9:394–408.  https://doi.org/10.2174/138920208785699580.CrossRefPubMedCentralPubMedGoogle Scholar
  67. 67.
    Burri N, et al. Methylation silencing and mutations of the p14ARF and p16INK4a genes in colon cancer. Lab Invest. 2001;81:217–29.CrossRefPubMedGoogle Scholar
  68. 68.
    Esteller M, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst. 2000;92:564–9.CrossRefPubMedGoogle Scholar
  69. 69.
    Myohanen SK, Baylin SB, Herman JG. Hypermethylation can selectively silence individual p16ink4A alleles in neoplasia. Cancer Res. 1998;58:591–3.PubMedGoogle Scholar
  70. 70.
    Esteller M, et al. Promoter hypermethylation of the DNA repair gene O(6)-methylguanine-DNA methyltransferase is associated with the presence of G:C to A:T transition mutations in p53 in human colorectal tumorigenesis. Cancer Res. 2001;61:4689–92.Google Scholar
  71. 71.
    Esteller M, et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res. 2000;60:2368–71.Google Scholar
  72. 72.
    Shen H, Laird PW. Interplay between the cancer genome and epigenome. Cell. 2013;153:38–55.  https://doi.org/10.1016/j.cell.2013.03.008.CrossRefPubMedCentralPubMedGoogle Scholar
  73. 73.
    Ishida E, et al. Promotor hypermethylation of p14ARF is a key alteration for progression of oral squamous cell carcinoma. Oral Oncol. 2005;41:614–22.  https://doi.org/10.1016/j.oraloncology.2005.02.003.CrossRefGoogle Scholar
  74. 74.
    Pierini S, et al. Promoter hypermethylation of CDKN2A, MGMT, MLH1, and DAPK genes in laryngeal squamous cell carcinoma and their associations with clinical profiles of the patients. Head Neck. 2014;36:1103–8.  https://doi.org/10.1002/hed.23413.CrossRefGoogle Scholar
  75. 75.
    Fan CY. Epigenetic alterations in head and neck cancer: prevalence, clinical significance, and implications. Curr Oncol Rep. 2004;6:152–61.CrossRefGoogle Scholar
  76. 76.
    Chen K, et al. Methylation of multiple genes as diagnostic and therapeutic markers in primary head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2007;133:1131–8.  https://doi.org/10.1001/archotol.133.11.1131.CrossRefGoogle Scholar
  77. 77.
    Demokan S, Dalay N. Role of DNA methylation in head and neck cancer. Clin Epigenetics. 2011;2:123–50.  https://doi.org/10.1007/s13148-011-0045-3.CrossRefPubMedCentralPubMedGoogle Scholar
  78. 78.
    Ovchinnikov DA, et al. Tumor-suppressor gene promoter hypermethylation in saliva of head and neck Cancer patients. Transl Oncol. 2012;5:321–6.CrossRefPubMedGoogle Scholar
  79. 79.
    Rettori MM, et al. Prognostic significance of TIMP3 hypermethylation in post-treatment salivary rinse from head and neck squamous cell carcinoma patients. Carcinogenesis. 2013;34:20–7.  https://doi.org/10.1093/carcin/bgs311.CrossRefGoogle Scholar
  80. 80.
    Rettori MM, et al. TIMP3 and CCNA1 hypermethylation in HNSCC is associated with an increased incidence of second primary tumors. J Transl Med. 2013;11:316.  https://doi.org/10.1186/1479-5876-11-316.CrossRefPubMedCentralPubMedGoogle Scholar
  81. 81.
    van Kempen PM, et al. Differences in methylation profiles between HPV-positive and HPV-negative oropharynx squamous cell carcinoma: a systematic review. Epigenetics. 2014;9:194–203.  https://doi.org/10.4161/epi.26881.CrossRefGoogle Scholar
  82. 82.
    Colacino JA, et al. Comprehensive analysis of DNA methylation in head and neck squamous cell carcinoma indicates differences by survival and clinicopathologic characteristics. PLoS One. 2013;8:e54742.  https://doi.org/10.1371/journal.pone.0054742.CrossRefPubMedCentralPubMedGoogle Scholar
  83. 83.
    Marsit CJ, et al. Epigenetic profiling reveals etiologically distinct patterns of DNA methylation in head and neck squamous cell carcinoma. Carcinogenesis. 2009;30:416–22.  https://doi.org/10.1093/carcin/bgp006.CrossRefPubMedCentralPubMedGoogle Scholar
  84. 84.
    Marsit CJ, McClean MD, Furniss CS, Kelsey KT. Epigenetic inactivation of the SFRP genes is associated with drinking, smoking and HPV in head and neck squamous cell carcinoma. Int J Cancer. 2006;119:1761–6.  https://doi.org/10.1002/ijc.22051.CrossRefGoogle Scholar
  85. 85.
    Poage GM, et al. Global hypomethylation identifies Loci targeted for hypermethylation in head and neck cancer. Clin Cancer Res. 2011;17:3579–89.  https://doi.org/10.1158/1078-0432.CCR-11-0044.CrossRefPubMedCentralPubMedGoogle Scholar
  86. 86.
    Richards KL, et al. Genome-wide hypomethylation in head and neck cancer is more pronounced in HPV-negative tumors and is associated with genomic instability. PLoS One. 2009;4:e4941.  https://doi.org/10.1371/journal.pone.0004941.CrossRefPubMedCentralPubMedGoogle Scholar
  87. 87.
    Sartor MA, et al. Genome-wide methylation and expression differences in HPV(+) and HPV(−) squamous cell carcinoma cell lines are consistent with divergent mechanisms of carcinogenesis. Epigenetics. 2011;6:777–87.CrossRefPubMedGoogle Scholar
  88. 88.
    Degli Esposti D, et al. Unique DNA methylation signature in HPV-positive head and neck squamous cell carcinomas. Genome Med. 2017;9:33.  https://doi.org/10.1186/s13073-017-0419-z.CrossRefPubMedCentralPubMedGoogle Scholar
  89. 89.
    Toyota M, et al. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A. 1999;96:8681–6.CrossRefPubMedGoogle Scholar
  90. 90.
    Garcia-Manero G, et al. DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. Clin Cancer Res. 2002;8:2217–24.Google Scholar
  91. 91.
    Fang F, et al. Breast cancer methylomes establish an epigenomic foundation for metastasis. Sci Transl Med. 2011;3:75ra25.  https://doi.org/10.1126/scitranslmed.3001875.CrossRefPubMedCentralPubMedGoogle Scholar
  92. 92.
    Noushmehr H, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010;17:510–22.  https://doi.org/10.1016/j.ccr.2010.03.017.CrossRefPubMedCentralPubMedGoogle Scholar
  93. 93.
    van den Bent MJ, et al. A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Clin Cancer Res. 2011;17:7148–55.  https://doi.org/10.1158/1078-0432.CCR-11-1274.CrossRefGoogle Scholar
  94. 94.
    Weisenberger DJ, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006;38:787–93.  https://doi.org/10.1038/ng1834.CrossRefGoogle Scholar
  95. 95.
    Figueroa ME, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010;18:553–67.  https://doi.org/10.1016/j.ccr.2010.11.015.CrossRefPubMedCentralPubMedGoogle Scholar
  96. 96.
    Hughes LA, et al. The CpG island methylator phenotype: what’s in a name? Cancer Res. 2013;73:5858–68.  https://doi.org/10.1158/0008-5472.CAN-12-4306.CrossRefGoogle Scholar
  97. 97.
    Jithesh PV, et al. The epigenetic landscape of oral squamous cell carcinoma. Br J Cancer. 2013;108:370–9.  https://doi.org/10.1038/bjc.2012.568.CrossRefPubMedCentralPubMedGoogle Scholar
  98. 98.
    Yoder JA, Walsh CP, Bestor TH. Cytosine methylation and the ecology of intragenomic parasites. Trends Genet. 1997;13:335–40.CrossRefGoogle Scholar
  99. 99.
    Liu WM, Maraia RJ, Rubin CM, Schmid CW. Alu transcripts: cytoplasmic localisation and regulation by DNA methylation. Nucleic Acids Res. 1994;22:1087–95.CrossRefPubMedGoogle Scholar
  100. 100.
    Paschos K, Allday MJ. Epigenetic reprogramming of host genes in viral and microbial pathogenesis. Trends Microbiol. 2010;18:439–47.  https://doi.org/10.1016/j.tim.2010.07.003.CrossRefPubMedCentralPubMedGoogle Scholar
  101. 101.
    Rosl F, Arab A, Klevenz B, zur Hausen H. The effect of DNA methylation on gene regulation of human papillomaviruses. J Gen Virol. 1993;74(Pt 5):791–801.  https://doi.org/10.1099/0022-1317-74-5-791.CrossRefGoogle Scholar
  102. 102.
    Lechner M, et al. Identification and functional validation of HPV-mediated hypermethylation in head and neck squamous cell carcinoma. Genome Med. 2013;5:15.  https://doi.org/10.1186/gm419.CrossRefPubMedCentralPubMedGoogle Scholar
  103. 103.
    Banister CE, Liu C, Pirisi L, Creek KE, Buckhaults PJ. Identification and characterization of HPV-independent cervical cancers. Oncotarget. 2017;8:13375–86.  https://doi.org/10.18632/oncotarget.14533.CrossRefPubMedCentralPubMedGoogle Scholar
  104. 104.
    Rothbart SB, et al. An interactive database for the assessment of histone antibody specificity. Mol Cell. 2015;59:502–11.  https://doi.org/10.1016/j.molcel.2015.06.022.CrossRefPubMedCentralPubMedGoogle Scholar
  105. 105.
    Mikkelsen TS, et al. Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature. 2007;448:553–60.  https://doi.org/10.1038/nature06008.CrossRefPubMedCentralPubMedGoogle Scholar
  106. 106.
    Pauler FM, et al. H3K27me3 forms BLOCs over silent genes and intergenic regions and specifies a histone banding pattern on a mouse autosomal chromosome. Genome Res. 2009;19:221–33.  https://doi.org/10.1101/gr.080861.108.CrossRefPubMedCentralPubMedGoogle Scholar
  107. 107.
    Volkel P, Angrand PO. The control of histone lysine methylation in epigenetic regulation. Biochimie. 2007;89:1–20.  https://doi.org/10.1016/j.biochi.2006.07.009.CrossRefGoogle Scholar
  108. 108.
    Barski A, et al. High-resolution profiling of histone methylations in the human genome. Cell. 2007;129:823–37.  https://doi.org/10.1016/j.cell.2007.05.009.CrossRefGoogle Scholar
  109. 109.
    Jones B, et al. The histone H3K79 methyltransferase Dot1L is essential for mammalian development and heterochromatin structure. PLoS Genet. 2008;4:e1000190.  https://doi.org/10.1371/journal.pgen.1000190.CrossRefPubMedCentralPubMedGoogle Scholar
  110. 110.
    Chen C, et al. Abnormal histone acetylation and methylation levels in esophageal squamous cell carcinomas. Cancer Investig. 2011;29:548–56.  https://doi.org/10.3109/07357907.2011.597810.CrossRefGoogle Scholar
  111. 111.
    Zhang K, et al. Comparative analysis of histone H3 and H4 post-translational modifications of esophageal squamous cell carcinoma with different invasive capabilities. J Proteome. 2015;112:180–9.  https://doi.org/10.1016/j.jprot.2014.09.004.CrossRefGoogle Scholar
  112. 112.
    Esteller M Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet. 2007;16 Spec No 1:R50–R59, doi: https://doi.org/10.1093/hmg/ddm018.
  113. 113.
    Lopez-Serra L, Esteller M. Proteins that bind methylated DNA and human cancer: reading the wrong words. Br J Cancer. 2008;98:1881–5.  https://doi.org/10.1038/sj.bjc.6604374.CrossRefPubMedCentralPubMedGoogle Scholar
  114. 114.
    Thomson JP, et al. CpG islands influence chromatin structure via the CpG-binding protein Cfp1. Nature. 2010;464:1082–6.  https://doi.org/10.1038/nature08924.CrossRefPubMedCentralPubMedGoogle Scholar
  115. 115.
    Zhang E, et al. H3K27 acetylation activated-long non-coding RNA CCAT1 affects cell proliferation and migration by regulating SPRY4 and HOXB13 expression in esophageal squamous cell carcinoma. Nucleic Acids Res. 2017;45:3086–101.  https://doi.org/10.1093/nar/gkw1247.CrossRefGoogle Scholar
  116. 116.
    Barneda-Zahonero B, Parra M. Histone deacetylases and cancer. Mol Oncol. 2012;6:579–89.  https://doi.org/10.1016/j.molonc.2012.07.003.CrossRefPubMedCentralPubMedGoogle Scholar
  117. 117.
    Sakuma T, et al. Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma. Int J Oncol. 2006;29:117–24.Google Scholar
  118. 118.
    Feinberg AP, Koldobskiy MA, Gondor A. Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. Nat Rev Genet. 2016;17:284–99.  https://doi.org/10.1038/nrg.2016.13.CrossRefPubMedCentralPubMedGoogle Scholar
  119. 119.
    Kantidakis T, et al. Mutation of cancer driver MLL2 results in transcription stress and genome instability. Genes Dev. 2016;30:408–20.  https://doi.org/10.1101/gad.275453.115.CrossRefPubMedCentralPubMedGoogle Scholar
  120. 120.
    Ortega-Molina A, et al. The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development. Nat Med. 2015;21:1199–208.  https://doi.org/10.1038/nm.3943.CrossRefPubMedCentralPubMedGoogle Scholar
  121. 121.
    Chen Y et al. MLL2, not MLL1, plays a major role in sustaining MLL-rearranged acute myeloid Leukemia. Cancer Cell. 2017;31:755–770 e756. doi: https://doi.org/10.1016/j.ccell.2017.05.002.
  122. 122.
    Rayasam GV, et al. NSD1 is essential for early post-implantation development and has a catalytically active SET domain. EMBO J. 2003;22:3153–63.  https://doi.org/10.1093/emboj/cdg288.CrossRefPubMedCentralPubMedGoogle Scholar
  123. 123.
    Nimura K, et al. A histone H3 lysine 36 trimethyltransferase links Nkx2-5 to Wolf-Hirschhorn syndrome. Nature. 2009;460:287–91.  https://doi.org/10.1038/nature08086.CrossRefGoogle Scholar
  124. 124.
    Kuo AJ, et al. NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming. Mol Cell. 2011;44:609–20.  https://doi.org/10.1016/j.molcel.2011.08.042.CrossRefPubMedCentralPubMedGoogle Scholar
  125. 125.
    Lu T, et al. Regulation of NF-kappaB by NSD1/FBXL11-dependent reversible lysine methylation of p65. Proc Natl Acad Sci USA. 2010;107:46–51.  https://doi.org/10.1073/pnas.0912493107.CrossRefGoogle Scholar
  126. 126.
    Morishita M, di Luccio E. Cancers and the NSD family of histone lysine methyltransferases. Biochim Biophys Acta. 2011;1816:158–63.  https://doi.org/10.1016/j.bbcan.2011.05.004.CrossRefGoogle Scholar
  127. 127.
    Iyer NG, Ozdag H, Caldas C. p300/CBP and cancer. Oncogene. 2004;23:4225–31.  https://doi.org/10.1038/sj.onc.1207118.CrossRefGoogle Scholar
  128. 128.
    El-Naggar AK, et al. Methylation, a major mechanism of p16/CDKN2 gene inactivation in head and neck squamous carcinoma. Am J Pathol. 1997;151:1767–74.PubMedCentralPubMedGoogle Scholar
  129. 129.
    Merlo A, et al. 5’ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med. 1995;1:686–92.CrossRefGoogle Scholar
  130. 130.
    Reed AL, et al. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res. 1996;56:3630–3.Google Scholar
  131. 131.
    Diesch J, et al. A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers. Clin Epigenetics. 2016;8:71.  https://doi.org/10.1186/s13148-016-0237-y.CrossRefPubMedCentralPubMedGoogle Scholar
  132. 132.
    Heerboth S, et al. Use of epigenetic drugs in disease: an overview. Genet Epigenet. 2014;6:9–19.  https://doi.org/10.4137/GEG.S12270.CrossRefPubMedCentralPubMedGoogle Scholar
  133. 133.
    Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov. 2006;5:37–50.  https://doi.org/10.1038/nrd1930.CrossRefPubMedGoogle Scholar
  134. 134.
    Greenblatt SM, Nimer SD. Chromatin modifiers and the promise of epigenetic therapy in acute leukemia. Leukemia. 2014;28:1396–406.  https://doi.org/10.1038/leu.2014.94.CrossRefPubMedCentralPubMedGoogle Scholar
  135. 135.
    Saba HI. Decitabine in the treatment of myelodysplastic syndromes. Ther Clin Risk Manag. 2007;3:807–17.PubMedCentralPubMedGoogle Scholar
  136. 136.
    Nervi C, De Marinis E, Codacci-Pisanelli G. Epigenetic treatment of solid tumours: a review of clinical trials. Clin Epigenetics. 2015;7:127.  https://doi.org/10.1186/s13148-015-0157-2.CrossRefPubMedCentralPubMedGoogle Scholar
  137. 137.
    Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist. 2007;12:1247–52.  https://doi.org/10.1634/theoncologist.12-10-1247.CrossRefPubMedGoogle Scholar
  138. 138.
    San-Miguel JF, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014;15:1195–206.  https://doi.org/10.1016/S1470-2045(14)70440-1.CrossRefPubMedGoogle Scholar
  139. 139.
    O’Connor OA, et al. Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study. J Clin Oncol. 2015;33:2492–9.  https://doi.org/10.1200/JCO.2014.59.2782.CrossRefPubMedCentralPubMedGoogle Scholar
  140. 140.
    Viet CT, et al. Decitabine rescues cisplatin resistance in head and neck squamous cell carcinoma. PLoS One. 2014;9:e112880.  https://doi.org/10.1371/journal.pone.0112880.CrossRefPubMedCentralPubMedGoogle Scholar
  141. 141.
    Glasspool RM, et al. A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer. Br J Cancer. 2014;110:1923–9.  https://doi.org/10.1038/bjc.2014.116.CrossRefPubMedCentralPubMedGoogle Scholar
  142. 142.
    Biktasova A, et al. Demethylation therapy as a targeted treatment for human papillomavirus-associated head and neck cancer. Clin Cancer Res. 2017;23:7276–87.  https://doi.org/10.1158/1078-0432.CCR-17-1438.CrossRefPubMedGoogle Scholar
  143. 143.
    Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet. 2009;10:32–42.  https://doi.org/10.1038/nrg2485.CrossRefPubMedCentralPubMedGoogle Scholar
  144. 144.
    Ropero S, Esteller M. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol. 2007;1:19–25.  https://doi.org/10.1016/j.molonc.2007.01.001.CrossRefPubMedCentralPubMedGoogle Scholar
  145. 145.
    Marks PA, Dokmanovic M. Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin Investig Drugs. 2005;14:1497–511.  https://doi.org/10.1517/13543784.14.12.1497.CrossRefGoogle Scholar
  146. 146.
    Blumenschein GR Jr, et al. Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Investig New Drugs. 2008;26:81–7.  https://doi.org/10.1007/s10637-007-9075-2.CrossRefGoogle Scholar
  147. 147.
    Brunetto AT, et al. First-in-human, pharmacokinetic and pharmacodynamic phase I study of Resminostat, an oral histone deacetylase inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2013;19:5494–504.  https://doi.org/10.1158/1078-0432.CCR-13-0735.CrossRefPubMedCentralPubMedGoogle Scholar
  148. 148.
    Haigentz M Jr, et al. Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer. Oral Oncol. 2012;48:1281–8.  https://doi.org/10.1016/j.oraloncology.2012.05.024.CrossRefPubMedCentralPubMedGoogle Scholar
  149. 149.
    Galloway TJ, et al. A phase I study of CUDC-101, a multitarget inhibitor of HDACs, EGFR, and HER2, in combination with chemoradiation in patients with head and neck squamous cell carcinoma. Clin Cancer Res. 2015;21:1566–73.  https://doi.org/10.1158/1078-0432.CCR-14-2820.CrossRefGoogle Scholar
  150. 150.
    Bally AP, Austin JW, Boss JM. Genetic and epigenetic regulation of PD-1 expression. J Immunol. 2016;196:2431–7.  https://doi.org/10.4049/jimmunol.1502643.CrossRefPubMedCentralPubMedGoogle Scholar
  151. 151.
    Chiappinelli KB, Zahnow CA, Ahuja N, Baylin SB. Combining epigenetic and immunotherapy to combat cancer. Cancer Res. 2016;76:1683–9.  https://doi.org/10.1158/0008-5472.CAN-15-2125.CrossRefPubMedCentralPubMedGoogle Scholar
  152. 152.
    Di Croce L, Helin K. Transcriptional regulation by Polycomb group proteins. Nat Struct Mol Biol. 2013;20:1147–55.  https://doi.org/10.1038/nsmb.2669.CrossRefPubMedGoogle Scholar
  153. 153.
    Margueron R, Reinberg D. The Polycomb complex PRC2 and its mark in life. Nature. 2011;469:343–9.  https://doi.org/10.1038/nature09784.CrossRefPubMedCentralPubMedGoogle Scholar
  154. 154.
    Kim KH, Roberts CW. Targeting EZH2 in cancer. Nat Med. 2016;22:128–34.  https://doi.org/10.1038/nm.4036.CrossRefPubMedCentralPubMedGoogle Scholar
  155. 155.
    Kurmasheva RT, et al. Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer. 2017;64.  https://doi.org/10.1002/pbc.26218.
  156. 156.
    Peri S, et al. NSD1- and NSD2-damaging mutations define a subset of laryngeal tumors with favorable prognosis. Nat Commun. 2017;8:1772.  https://doi.org/10.1038/s41467-017-01877-7.CrossRefPubMedCentralPubMedGoogle Scholar
  157. 157.
    Rogawski DS, Grembecka J, Cierpicki T. H3K36 methyltransferases as cancer drug targets: rationale and perspectives for inhibitor development. Future Med Chem. 2016;8:1589–607.  https://doi.org/10.4155/fmc-2016-0071.CrossRefPubMedCentralPubMedGoogle Scholar
  158. 158.
    Esteller M, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000;343:1350–4.  https://doi.org/10.1056/NEJM200011093431901.CrossRefPubMedGoogle Scholar
  159. 159.
    Vogelstein B, et al. Cancer genome landscapes. Science. 2013;339:1546–58.  https://doi.org/10.1126/science.1235122.CrossRefPubMedCentralPubMedGoogle Scholar
  160. 160.
    Chung CH, et al. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell. 2004;5:489–500.CrossRefPubMedGoogle Scholar
  161. 161.
    Walter V, et al. Molecular subtypes in head and neck cancer exhibit distinct patterns of chromosomal gain and loss of canonical cancer genes. PLoS One. 2013;8:e56823.  https://doi.org/10.1371/journal.pone.0056823.CrossRefPubMedCentralPubMedGoogle Scholar
  162. 162.
    Chung CH, et al. Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-kappaB signaling as characteristics of a high-risk head and neck squamous cell carcinoma. Cancer Res. 2006;66:8210–8.  https://doi.org/10.1158/0008-5472.CAN-06-1213.CrossRefPubMedGoogle Scholar
  163. 163.
    Buffa FM, Harris AL, West CM, Miller CJ. Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene. Br J Cancer. 2010;102:428–35.  https://doi.org/10.1038/sj.bjc.6605450.CrossRefPubMedCentralPubMedGoogle Scholar
  164. 164.
    Eschrich SA, et al. A gene expression model of intrinsic tumor radiosensitivity: prediction of response and prognosis after chemoradiation. Int J Radiat Oncol Biol Phys. 2009;75:489–96.  https://doi.org/10.1016/j.ijrobp.2009.06.014.CrossRefPubMedCentralPubMedGoogle Scholar
  165. 165.
    Roepman P, et al. An expression profile for diagnosis of lymph node metastases from primary head and neck squamous cell carcinomas. Nat Genet. 2005;37:182–6.  https://doi.org/10.1038/ng1502.CrossRefPubMedGoogle Scholar
  166. 166.
    Toustrup K, et al. Development of a hypoxia gene expression classifier with predictive impact for hypoxic modification of radiotherapy in head and neck cancer. Cancer Res. 2011;71:5923–31.  https://doi.org/10.1158/0008-5472.CAN-11-1182.CrossRefGoogle Scholar
  167. 167.
    Winter SC, et al. Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers. Cancer Res. 2007;67:3441–9.  https://doi.org/10.1158/0008-5472.CAN-06-3322.CrossRefPubMedGoogle Scholar
  168. 168.
    Onken MD, et al. A surprising cross-species conservation in the genomic landscape of mouse and human oral cancer identifies a transcriptional signature predicting metastatic disease. Clin Cancer Res. 2014;20:2873–84.  https://doi.org/10.1158/1078-0432.CCR-14-0205.CrossRefPubMedCentralPubMedGoogle Scholar
  169. 169.
    Overgaard J, et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish head and neck Cancer study (DAHANCA) protocol 5-85. Radiother Oncol. 1998;46:135–46.CrossRefPubMedGoogle Scholar
  170. 170.
    Toustrup K, et al. Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck. Radiother Oncol. 2012;102:122–9.  https://doi.org/10.1016/j.radonc.2011.09.010.CrossRefPubMedGoogle Scholar
  171. 171.
    Chalise P, Koestler DC, Bimali M, Yu Q, Fridley BL. Integrative clustering methods for high-dimensional molecular data. Transl Cancer Res. 2014;3:202–16.  https://doi.org/10.3978/j.issn.2218-676X.2014.06.03.CrossRefPubMedCentralPubMedGoogle Scholar
  172. 172.
    Mo Q, et al. A fully Bayesian latent variable model for integrative clustering analysis of multi-type omics data. Biostatistics. 2018;19:71–86.  https://doi.org/10.1093/biostatistics/kxx017.CrossRefPubMedGoogle Scholar
  173. 173.
    Mo Q, et al. Pattern discovery and cancer gene identification in integrated cancer genomic data. Proc Natl Acad Sci USA. 2013;110:4245–50.  https://doi.org/10.1073/pnas.1208949110.CrossRefPubMedGoogle Scholar
  174. 174.
    Shen R, Olshen AB, Ladanyi M. Integrative clustering of multiple genomic data types using a joint latent variable model with application to breast and lung cancer subtype analysis. Bioinformatics. 2009;25:2906–12.  https://doi.org/10.1093/bioinformatics/btp543.CrossRefPubMedCentralPubMedGoogle Scholar
  175. 175.
    Zhang S, et al. Discovery of multi-dimensional modules by integrative analysis of cancer genomic data. Nucleic Acids Res. 2012;40:9379–91.  https://doi.org/10.1093/nar/gks725.CrossRefPubMedCentralPubMedGoogle Scholar
  176. 176.
    Choufani S, et al. NSD1 mutations generate a genome-wide DNA methylation signature. Nat Commun. 2015;6:10207.  https://doi.org/10.1038/ncomms10207.CrossRefPubMedCentralPubMedGoogle Scholar
  177. 177.
    Baubec T, et al. Genomic profiling of DNA methyltransferases reveals a role for DNMT3B in genic methylation. Nature. 2015;520:243–7.  https://doi.org/10.1038/nature14176.CrossRefGoogle Scholar
  178. 178.
    Li H, et al. The histone methyltransferase SETDB1 and the DNA methyltransferase DNMT3A interact directly and localize to promoters silenced in cancer cells. J Biol Chem. 2006;281:19489–500.  https://doi.org/10.1074/jbc.M513249200.CrossRefGoogle Scholar
  179. 179.
    Papillon-Cavanagh S, et al. Impaired H3K36 methylation defines a subset of head and neck squamous cell carcinomas. Nat Genet. 2017;49:180–5.  https://doi.org/10.1038/ng.3757.CrossRefPubMedCentralPubMedGoogle Scholar
  180. 180.
    Goffin J, Eisenhauer E. DNA methyltransferase inhibitors-state of the art. Ann Oncol. 2002;13:1699–716.CrossRefGoogle Scholar
  181. 181.
    Plummer R, et al. Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors. Clin Cancer Res. 2009;15:3177–83.  https://doi.org/10.1158/1078-0432.CCR-08-2859.CrossRefGoogle Scholar
  182. 182.
    Halby L, et al. Rapid synthesis of new DNMT inhibitors derivatives of procainamide. ChemBioChem. 2012;13:157–65.  https://doi.org/10.1002/cbic.201100522.CrossRefGoogle Scholar
  183. 183.
    Stresemann C, Brueckner B, Musch T, Stopper H, Lyko F. Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines. Cancer Res. 2006;66:2794–800.  https://doi.org/10.1158/0008-5472.CAN-05-2821.CrossRefGoogle Scholar
  184. 184.
    Esquela-Kerscher A, Slack FJ. Oncomirs – microRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259–69.  https://doi.org/10.1038/nrc1840.CrossRefGoogle Scholar
  185. 185.
    D’Angelo B, Benedetti E, Cimini A, Giordano A. MicroRNAs: a puzzling tool in cancer diagnostics and therapy. Anticancer Res. 2016;36:5571–5.  https://doi.org/10.21873/anticanres.11142.CrossRefGoogle Scholar
  186. 186.
    Kozaki K, Imoto I, Mogi S, Omura K, Inazawa J. Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res. 2008;68:2094–105.  https://doi.org/10.1158/0008-5472.CAN-07-5194.CrossRefGoogle Scholar
  187. 187.
    Reis PP, et al. Programmed cell death 4 loss increases tumor cell invasion and is regulated by miR-21 in oral squamous cell carcinoma. Mol Cancer. 2010;9:238.  https://doi.org/10.1186/1476-4598-9-238.CrossRefPubMedCentralPubMedGoogle Scholar
  188. 188.
    Allegra E, Trapasso S, Pisani D, Puzzo L. The role of BMI1 as a biomarker of cancer stem cells in head and neck cancer: a review. Oncology. 2014;86:199–205.  https://doi.org/10.1159/000358598.CrossRefGoogle Scholar
  189. 189.
    An Y, Ongkeko WM. ABCG2: the key to chemoresistance in cancer stem cells? Expert Opin Drug Metab Toxicol. 2009;5:1529–42.  https://doi.org/10.1517/17425250903228834.CrossRefGoogle Scholar
  190. 190.
    Grimm M, et al. ABCB5 expression and cancer stem cell hypothesis in oral squamous cell carcinoma. Eur J Cancer. 2012;48:3186–97.  https://doi.org/10.1016/j.ejca.2012.05.027.CrossRefGoogle Scholar
  191. 191.
    Hoffmeyer K, et al. Wnt/beta-catenin signaling regulates telomerase in stem cells and cancer cells. Science. 2012;336:1549–54.  https://doi.org/10.1126/science.1218370.CrossRefGoogle Scholar
  192. 192.
    Momparler RL, Cote S. Targeting of cancer stem cells by inhibitors of DNA and histone methylation. Expert Opin Investig Drugs. 2015;24:1031–43.  https://doi.org/10.1517/13543784.2015.1051220.CrossRefGoogle Scholar
  193. 193.
    Naik PP, et al. Implications of cancer stem cells in developing therapeutic resistance in oral cancer. Oral Oncol. 2016;62:122–35.  https://doi.org/10.1016/j.oraloncology.2016.10.008.CrossRefGoogle Scholar
  194. 194.
    Shukla S, Meeran SM. Epigenetics of cancer stem cells: pathways and therapeutics. Biochim Biophys Acta. 2014;1840:3494–502.  https://doi.org/10.1016/j.bbagen.2014.09.017.CrossRefGoogle Scholar
  195. 195.
    Medina PP, Nolde M, Slack FJ. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature. 2010;467:86–90.  https://doi.org/10.1038/nature09284.CrossRefGoogle Scholar
  196. 196.
    Gaykalova DA, et al. Outlier analysis defines zinc finger gene family DNA methylation in Tumors and saliva of head and neck Cancer patients. PLoS One. 2015;10:e0142148.  https://doi.org/10.1371/journal.pone.0142148.CrossRefPubMedCentralPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Suraj Peri
    • 1
  • Andrew J. Andrews
    • 2
  • Aarti Bhatia
    • 3
  • Ranee Mehra
    • 4
    • 4
  1. 1.Biostatistics and Bioinformatics DivisionFox Chase Cancer CenterPhiladelphiaUSA
  2. 2.Program in Cancer BiologyFox Chase Cancer CenterPhiladelphiaUSA
  3. 3.Department of Internal MedicineYale School of Medicine and Yale Cancer CenterNew HavenUSA
  4. 4.Department of OncologyJohns Hopkins University School of MedicineBaltimoreUSA

Personalised recommendations